Dr. Reddy’s Laboratories Ltd (NYSE:RDY) – Equities researchers at Jefferies Group lowered their FY2018 EPS estimates for Dr. Reddy’s Laboratories in a research note issued to investors on Tuesday. Jefferies Group analyst P. Nahar now expects that the company will earn $1.14 per share for the year, down from their previous estimate of $1.28. Jefferies Group has a “Underperform” rating and a $30.51 price objective on the stock. Jefferies Group also issued estimates for Dr. Reddy’s Laboratories’ FY2019 earnings at $1.88 EPS and FY2020 earnings at $2.21 EPS.

Several other research firms have also recently commented on RDY. Zacks Investment Research upgraded shares of Dr. Reddy’s Laboratories from a “strong sell” rating to a “hold” rating in a report on Friday, July 14th. CLSA cut shares of Dr. Reddy’s Laboratories from an “underperform” rating to a “sell” rating in a report on Friday, July 28th. BidaskClub cut shares of Dr. Reddy’s Laboratories from a “hold” rating to a “sell” rating in a report on Monday, July 31st. Finally, Morgan Stanley upgraded shares of Dr. Reddy’s Laboratories from an “equal weight” rating to an “overweight” rating in a report on Thursday, September 21st. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. Dr. Reddy’s Laboratories presently has a consensus rating of “Hold” and an average target price of $30.51.

WARNING: “Dr. Reddy’s Laboratories Ltd (RDY) to Post FY2018 Earnings of $1.14 Per Share, Jefferies Group Forecasts” was first reported by Watch List News and is the property of of Watch List News. If you are reading this article on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this article can be viewed at https://www.watchlistnews.com/dr-reddys-laboratories-ltd-rdy-to-post-fy2018-earnings-of-1-14-per-share-jefferies-group-forecasts/1678075.html.

Dr. Reddy’s Laboratories (NYSE RDY) traded up $1.08 during mid-day trading on Thursday, reaching $36.75. The company had a trading volume of 425,297 shares, compared to its average volume of 314,180. The company has a market cap of $6.24 billion, a P/E ratio of 36.52, a price-to-earnings-growth ratio of 11.00 and a beta of 0.40. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.10 and a current ratio of 1.46.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Alps Advisors Inc. raised its position in Dr. Reddy’s Laboratories by 29.9% during the third quarter. Alps Advisors Inc. now owns 28,476 shares of the company’s stock valued at $1,016,000 after acquiring an additional 6,550 shares in the last quarter. Aperio Group LLC raised its position in Dr. Reddy’s Laboratories by 11.3% during the third quarter. Aperio Group LLC now owns 181,974 shares of the company’s stock valued at $6,493,000 after acquiring an additional 18,459 shares in the last quarter. First Trust Advisors LP raised its position in Dr. Reddy’s Laboratories by 22.9% during the third quarter. First Trust Advisors LP now owns 411,790 shares of the company’s stock valued at $14,693,000 after acquiring an additional 76,797 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in Dr. Reddy’s Laboratories during the second quarter valued at approximately $286,000. Finally, Migdal Insurance & Financial Holdings Ltd. raised its position in Dr. Reddy’s Laboratories by 0.4% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 14,160 shares of the company’s stock valued at $582,000 after acquiring an additional 60 shares in the last quarter. 15.23% of the stock is currently owned by hedge funds and other institutional investors.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics).

Earnings History and Estimates for Dr. Reddy`s Laboratories (NYSE:RDY)

Receive News & Ratings for Dr. Reddy's Laboratories Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Reddy's Laboratories Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.